Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
A Phase 3 Comparative Study of TAP-144-SR(6M) in Prostate Cancer Patients Previously Treated With Hormonal Therapy
Phase 3
Completed
- Conditions
- Prostate Cancer
- Interventions
- Drug: TAP-144-SR(6M)Drug: TAP-144-SR(3M)
- First Posted Date
- 2012-03-07
- Last Posted Date
- 2015-07-21
- Lead Sponsor
- Takeda
- Target Recruit Count
- 160
- Registration Number
- NCT01546623
A Comparison of the Safety and Immunogenicity of Various Schedules of Dengue Vaccine in Healthy Adult Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Biological: Takeda's Tetravalent Dengue Vaccine Candidate (TDV)Biological: TDV New FormulationDrug: PlaceboDrug: New Formulation Placebo
- First Posted Date
- 2012-03-02
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Takeda
- Target Recruit Count
- 140
- Registration Number
- NCT01542632
- Locations
- 🇺🇸
Heart Center of the Rockies, Fort Collins, Colorado, United States
🇺🇸University of Texas Medical Branch, Galveston, Texas, United States
🇺🇸Advanced Clinical Research, West Jordan, Utah, United States
Study of Combination Therapy With SYR-322
- First Posted Date
- 2012-01-31
- Last Posted Date
- 2013-11-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 67
- Registration Number
- NCT01521962
Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Biological: TDVBiological: Placebo
- First Posted Date
- 2012-01-18
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- Takeda
- Target Recruit Count
- 360
- Registration Number
- NCT01511250
- Locations
- 🇵🇷
University of Puerto Rico School of Medicine, San Juan, Puerto Rico
🇵🇷Latin Clinical Trial Center, San Juan, Puerto Rico
🇸🇬National University Hospital, Singapore, Singapore
Efficacy of TAK-438, Amoxicillin and Clarithromycin in the First Line Eradication of H. Pylori
Phase 3
Completed
- Conditions
- H. Pylori Infection
- Interventions
- First Posted Date
- 2012-01-06
- Last Posted Date
- 2013-11-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 650
- Registration Number
- NCT01505127
Comparison of Efficacy and Safety of TachoSil® Versus Surgicel® Original for the Secondary Hemostatic Treatment of Needle Hole Bleeding in Vascular Surgery
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Takeda
- Target Recruit Count
- 150
- Registration Number
- NCT01500135
- Locations
- 🇺🇸
Nycomed Investigational Site, Bellevue, Washington, United States
Magnesium Pantoprazole 20mg b.i.d. vs Magnesium Pantoprazole 40mg q.d. on Intragastric Acid Inhibition
Phase 3
Withdrawn
- Conditions
- Gastric pH Control
- Interventions
- Drug: Magnesium Pantoprazole 20 mgDrug: Magnesium Pantoprazole 40 mgDrug: Placebo
- First Posted Date
- 2011-12-26
- Last Posted Date
- 2012-09-17
- Lead Sponsor
- Takeda
- Registration Number
- NCT01499693
- Locations
- 🇲🇽
Hospital Español de Mexico, Mexico City, Mexico
A Trial to Investigate the Pharmacokinetics (PK) of Single Doses of 200 µg, 400 µg and 2 x 400 µg of Intranasal Fentanyl Spray (INFS) in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: INFS (Intranasal Fentanyl Spray)
- First Posted Date
- 2011-12-22
- Last Posted Date
- 2012-10-02
- Lead Sponsor
- Takeda
- Target Recruit Count
- 20
- Registration Number
- NCT01497288
- Locations
- 🇩🇪
Nycomed Investigational Site, Mannheim, Germany
TAK-875 Glimepiride Drug-Interaction Study
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2012-09-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 28
- Registration Number
- NCT01496443
Effect of Febuxostat on Blood Pressure
- First Posted Date
- 2011-12-21
- Last Posted Date
- 2015-08-31
- Lead Sponsor
- Takeda
- Target Recruit Count
- 121
- Registration Number
- NCT01496469
© Copyright 2025. All Rights Reserved by MedPath